Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Active, not recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Local Institution - 0014 Mobile, Alabama, United States
  • Local Institution - 0477 Anchorage, Alaska, United States
  • Local Institution - 0452 Phoenix, Arizona, United States
  • Local Institution - 0342 San Francisco, California, United States
View all 325 locations
View Trial Details
Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute Louisville, Kentucky, United States
  • John Theurer Cancer Center Hackensack, New Jersey, United States
  • Novant Health Charlotte, North Carolina, United States
  • Institut - Jules Bordet Anderlecht, Belgium
View all 88 locations
View Trial Details
Active, not recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, not recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University Of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 47 locations
View Trial Details
Active, not recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The Oncology Institute (TOI) Clinical Research Cerritos, California, United States
  • Norton Cancer Institute, St. Matthews Louisville, Kentucky, United States
View all 38 locations
View Trial Details
Active, not recruiting

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Sparks Regional Medical Center Fort Smith, Arkansas, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
View all 391 locations
View Trial Details

Related conditions